HTML Microdata document

This HTML5 document contains 80 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n16	http://www.rxlist.com/cgi/generic3/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n27	http://linked.opendata.cz/resource/AHFS/
n14	http://linked.opendata.cz/resource/mesh/concept/
n23	http://linked.opendata.cz/resource/drugbank/drug/DB00659/identifier/pubchem-compound/
n25	http://linked.opendata.cz/resource/drugbank/company/
foaf	http://xmlns.com/foaf/0.1/
n17	http://linked.opendata.cz/resource/drugbank/dosage/
n24	http://linked.opendata.cz/resource/drugbank/drug/DB00659/identifier/pubchem-substance/
n7	http://linked.opendata.cz/resource/drugbank/drug/DB00659/identifier/kegg-drug/
n6	http://linked.opendata.cz/resource/drugbank/drug/DB00659/identifier/drugbank/
n19	http://bio2rdf.org/drugbank:
adms	http://www.w3.org/ns/adms#
n4	http://linked.opendata.cz/resource/drugbank/drug/DB00659/identifier/national-drug-code-directory/
n22	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n21	http://linked.opendata.cz/resource/drugbank/medicinal-product/
n10	http://linked.opendata.cz/resource/drugbank/drug/DB00659/identifier/chemspider/
n13	http://linked.opendata.cz/ontology/mesh/
owl	http://www.w3.org/2002/07/owl#
n9	http://linked.opendata.cz/ontology/drugbank/
n12	http://www.drugs.com/cdi/
n15	http://linked.opendata.cz/resource/drugbank/property/
n8	http://linked.opendata.cz/resource/drugbank/drug/DB00659/identifier/chebi/
n29	http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdh	http://www.w3.org/2001/XMLSchema#
n26	http://linked.opendata.cz/ontology/sukl/drug/
n28	http://linked.opendata.cz/resource/drugbank/drug/DB00659/identifier/wikipedia/
n30	http://linked.opendata.cz/resource/atc/
n5	http://linked.opendata.cz/resource/drugbank/drug/DB00659/identifier/pharmgkb/

Statements

Subject Item: n2:DB00659
rdf:type: n9:Drug
n9:description: Acamprosate, also known by the brand name Campral™, is a drug used for treating alcohol dependence. Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcoholism, possibly by blocking glutaminergic N-methyl-D-aspartate receptors, while gamma-aminobutyric acid type A receptors are activated. Reports indicate that acamprosate only works with a combination of attending support groups and abstinence from alcohol. Certain serious side effects include allergic reactions, irregular heartbeats, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Acamprosate should not be taken by people with kidney problems or allergies to the drug.
n9:dosage: n17:271B63D5-363D-11E5-9242-09173F13E4C5 n17:271B63D6-363D-11E5-9242-09173F13E4C5 n17:271B63D7-363D-11E5-9242-09173F13E4C5
n9:generalReferences: # Williams SH: Medications for treating alcohol dependence. Am Fam Physician. 2005 Nov 1;72(9):1775-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16300039 # Mason BJ: Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001;62 Suppl 20:42-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11584875 # Mason BJ, Goodman AM, Chabac S, Lehert P: Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006 Aug;40(5):383-93. Epub 2006 Mar 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16546214 # Feeney GF, Connor JP, Young RM, Tucker J, McPherson A: Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 2006 May-Jun;41(3):321-7. Epub 2006 Feb 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16467406 # Tsai G, Coyle JT: The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med. 1998;49:173-84. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9509257 # Wilde MI, Wagstaff AJ: Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs. 1997 Jun;53(6):1038-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9179530
n9:group: approved investigational
n9:halfLife: 20 - 33 hours
n9:indication: For the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation
n9:manufacturer: n25:271B63D1-363D-11E5-9242-09173F13E4C5
owl:sameAs: n19:DB00659 n22:DB00659
dcterms:title: Acamprosate
adms:identifier: n4:0456-3330-01 n5:PA10344 n6:DB00659 n7:D02780 n8:51041 n10:64300 n23:71158 n24:46506657 n28:Acamprosate
n9:mechanismOfAction: The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. in vitro and in vivo studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance. It seems to inhibit NMDA receptors while activating GABA receptors.
n9:packager: n25:271B63CD-363D-11E5-9242-09173F13E4C5 n25:271B63D0-363D-11E5-9242-09173F13E4C5 n25:271B63CE-363D-11E5-9242-09173F13E4C5 n25:271B63CF-363D-11E5-9242-09173F13E4C5
n9:routeOfElimination: Following oral administration of CAMPRAL®, the major route of excretion is via the kidneys as acamprosate.
n9:synonym: Acamprosato 3-Acetamido-1-propanesulfonic acid N-Acetylhomotaurine Acamprosatum N-acetyl homotaurine
n9:toxicity: In all reported cases of acute overdosage with acamprosate (total reported doses of up to 56 grams of acamprosate calcium), the only symptom that could be reasonably associated with acamprosate was diarrhea.
n9:volumeOfDistribution: * 72 to 109 L
n26:hasAHFSCode: n27:28-92%20
n9:foodInteraction: Take without regard to meals. Taking the product with food reduces its Cmax by 42% and total drug exposure by 23% (not considered significant).
n9:proteinBinding: Non detectable
n9:salt
n13:hasConcept: n14:M0128674
foaf:page: n12:acamprosate.html n16:campral.htm n29:cam1691.shtml
n9:IUPAC-Name: n15:271B63DC-363D-11E5-9242-09173F13E4C5
n9:InChI: n15:271B63E2-363D-11E5-9242-09173F13E4C5
n9:Molecular-Formula: n15:271B63E1-363D-11E5-9242-09173F13E4C5
n9:Molecular-Weight: n15:271B63DE-363D-11E5-9242-09173F13E4C5
n9:Monoisotopic-Weight: n15:271B63DF-363D-11E5-9242-09173F13E4C5
n9:SMILES: n15:271B63E0-363D-11E5-9242-09173F13E4C5
n9:Water-Solubility: n15:271B63DA-363D-11E5-9242-09173F13E4C5
n9:logP: n15:271B63D8-363D-11E5-9242-09173F13E4C5 n15:271B63DB-363D-11E5-9242-09173F13E4C5 n15:271B63F2-363D-11E5-9242-09173F13E4C5
n9:logS: n15:271B63D9-363D-11E5-9242-09173F13E4C5
n26:hasATCCode: n30:N07BB03
n9:H-Bond-Acceptor-Count: n15:271B63E8-363D-11E5-9242-09173F13E4C5
n9:H-Bond-Donor-Count: n15:271B63E9-363D-11E5-9242-09173F13E4C5
n9:InChIKey: n15:271B63E3-363D-11E5-9242-09173F13E4C5
n9:Polar-Surface-Area--PSA-: n15:271B63E4-363D-11E5-9242-09173F13E4C5
n9:Polarizability: n15:271B63E6-363D-11E5-9242-09173F13E4C5
n9:Refractivity: n15:271B63E5-363D-11E5-9242-09173F13E4C5
n9:Rotatable-Bond-Count: n15:271B63E7-363D-11E5-9242-09173F13E4C5
n9:absorption: The absolute bioavailability of acamprosate after oral administration is about 11%. The food effect on absorption is not clinically significant and no adjustment of dose is necessary.
n9:affectedOrganism: Humans and other mammals
n9:casRegistryNumber: 77337-76-9
n9:category
n9:containedIn: n21:271B63D2-363D-11E5-9242-09173F13E4C5 n21:271B63D3-363D-11E5-9242-09173F13E4C5 n21:271B63D4-363D-11E5-9242-09173F13E4C5
n9:Bioavailability: n15:271B63EE-363D-11E5-9242-09173F13E4C5
n9:Ghose-Filter: n15:271B63F0-363D-11E5-9242-09173F13E4C5
n9:MDDR-Like-Rule: n15:271B63F1-363D-11E5-9242-09173F13E4C5
n9:Number-of-Rings: n15:271B63ED-363D-11E5-9242-09173F13E4C5
n9:Physiological-Charge: n15:271B63EC-363D-11E5-9242-09173F13E4C5
n9:Rule-of-Five: n15:271B63EF-363D-11E5-9242-09173F13E4C5
n9:Traditional-IUPAC-Name: n15:271B63DD-363D-11E5-9242-09173F13E4C5
n9:pKa--strongest-acidic-: n15:271B63EA-363D-11E5-9242-09173F13E4C5
n9:pKa--strongest-basic-: n15:271B63EB-363D-11E5-9242-09173F13E4C5